<DOC>
	<DOCNO>NCT00069927</DOCNO>
	<brief_summary>RATIONALE : Stimulant drug dextroamphetamine-amphetamine methylphenidate may help improve memory , attention , think problem cause central nervous system ( CNS ) treatment cancer , may help decrease depression . PURPOSE : This randomized phase II trial study dextroamphetamine-amphetamine see well work compare methylphenidate treat depression problem memory , attention , think child undergone CNS treatment cancer . This trial also study often depression see medication might help .</brief_summary>
	<brief_title>Adderall XR Compared With Concerta Treating Young Cancer Patients With Memory , Attention , Depression</brief_title>
	<detailed_description>OBJECTIVES : - Compare response rate pediatric cancer patient treatment-related neurocognitive sequela treat dextroamphetamine-amphetamine ( Adderall-XR® ) v methylphenidate ( Concerta® ) . - Compare durability response 12 week patient show response 3 week treatment drug . - Determine whether patient response one study drug respond study drug . - Determine prevalence depression possible response neurostimulant therapy patient population . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral dextroamphetamine-amphetamine daily 3 week . Patients achieve response ( base neurocognitive test ) continue treatment total 12 week . Patients response 3 week cross arm II 48-hour washout period . - Arm II : Patients receive oral methylphenidate daily 3 week . Responding patient continue treatment total 12 week . Patients response 3 week cross arm I 48-hour washout period . Depression neurocognitive function assess baseline , 3 week , end study . PROJECTED ACCRUAL : A total 177 patient ( approximately 88 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<mesh_term>Adderall</mesh_term>
	<criteria>INCLUSION CRITERIA : Between age 617 time study participation . Have diagnosis malignancy require CNS treatment surgery and/or irradiation and/or intrathecal chemotherapy . ( Patients treat systemic chemotherapy alone eligible participate ) Off treatment cancer free minimum 6 month . Have proficiency English . EXCLUSION CRITERIA : Patients estimate intelligence quotient ( IQ ) less 65 ( base Wide Range Achievement Test ( WRAT3 ) Reading subtest ) eligible continue study . At least one standard deviation level performance predict IQ least 2 3 WISCIII subtests . Diagnosed Attention Deficit Disorder ( ADD ) Attention Deficit Hyperactivity Disorder ( ADHD ) prior cancer diagnosis . Currently take antidepressant , antipsychotic , stimulant . Are blind . Have glaucoma . Family history motor phonic tic Tourette 's syndrome . Have seizure control antiepileptic drug . ( Note : Patients experience seizure activity , stable dose antiepileptic drug least 12 week may participate ) Taking monoamine oxidase ( MAO ) inhibitor . Have history cardiovascular disease , uncontrolled hypertension hyperthyroidism .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>depression</keyword>
	<keyword>neurotoxicity</keyword>
</DOC>